1. Home
  2. DHF vs ACIU Comparison

DHF vs ACIU Comparison

Compare DHF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHF
  • ACIU
  • Stock Information
  • Founded
  • DHF 1998
  • ACIU 2003
  • Country
  • DHF United States
  • ACIU Switzerland
  • Employees
  • DHF N/A
  • ACIU N/A
  • Industry
  • DHF Finance Companies
  • ACIU Biotechnology: Pharmaceutical Preparations
  • Sector
  • DHF Finance
  • ACIU Health Care
  • Exchange
  • DHF Nasdaq
  • ACIU Nasdaq
  • Market Cap
  • DHF 185.7M
  • ACIU 213.3M
  • IPO Year
  • DHF N/A
  • ACIU 2016
  • Fundamental
  • Price
  • DHF $2.55
  • ACIU $3.42
  • Analyst Decision
  • DHF
  • ACIU Strong Buy
  • Analyst Count
  • DHF 0
  • ACIU 2
  • Target Price
  • DHF N/A
  • ACIU $10.00
  • AVG Volume (30 Days)
  • DHF 451.1K
  • ACIU 432.8K
  • Earning Date
  • DHF 01-01-0001
  • ACIU 11-04-2025
  • Dividend Yield
  • DHF 7.65%
  • ACIU N/A
  • EPS Growth
  • DHF N/A
  • ACIU N/A
  • EPS
  • DHF N/A
  • ACIU N/A
  • Revenue
  • DHF N/A
  • ACIU $5,482,957.00
  • Revenue This Year
  • DHF N/A
  • ACIU N/A
  • Revenue Next Year
  • DHF N/A
  • ACIU $1,022.98
  • P/E Ratio
  • DHF N/A
  • ACIU N/A
  • Revenue Growth
  • DHF N/A
  • ACIU N/A
  • 52 Week Low
  • DHF $2.06
  • ACIU $1.43
  • 52 Week High
  • DHF $2.39
  • ACIU $4.00
  • Technical
  • Relative Strength Index (RSI)
  • DHF 42.17
  • ACIU 55.05
  • Support Level
  • DHF $2.56
  • ACIU $3.11
  • Resistance Level
  • DHF $2.58
  • ACIU $3.70
  • Average True Range (ATR)
  • DHF 0.02
  • ACIU 0.40
  • MACD
  • DHF -0.00
  • ACIU -0.01
  • Stochastic Oscillator
  • DHF 25.83
  • ACIU 56.20

About DHF BNY Mellon High Yield Strategies Fund

BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: